Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability
November 1, 2021
November 1, 2021
MedinCell announces participation in the Jefferies London Healthcare Conference 2021
October 25, 2021
October 25, 2021
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
October 21, 2021
October 21, 2021
MedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting
September 10, 2021
September 10, 2021
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
August 31, 2021
August 31, 2021
Evaluation of Loco-Regional Skin Toxicity Induced by an In Situ Forming Depot after a Single Subcutaneous Injection at Different Volumes and Flow Rates in Göttingen Minipigs
August 26, 2021
August 26, 2021
Impact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology
August 10, 2021
August 10, 2021
Participation terms in the MedinCell Combined General Meeting
August 4, 2021
August 4, 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
July 28, 2021
July 28, 2021
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
